Phase I dose-ranging trial of OMS 824 in healthy volunteers.

Trial Profile

Phase I dose-ranging trial of OMS 824 in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2014

At a glance

  • Drugs OMS 824 (Primary)
  • Indications Cognition disorders; Schizophrenia
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Apr 2014 Results will be presented at the 2014 Biennial Conference of the Schizophrenia International Research Society (SIRS) according to an Omeros Corporation media release.
    • 26 Mar 2013 Status changed from recruiting to completed.
    • 26 Mar 2013 Results from multiple dose part of study published in an Omeros media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top